{"links":{"html":"https://www.erudio.com/reports/checkmate-744-nct02927769","json":"https://www.erudio.com/reports/checkmate-744-nct02927769.json","markdown":"https://www.erudio.com/reports/checkmate-744-nct02927769.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"checkmate-744-02927769"}},"request":"https://www.erudio.com/contact?report=checkmate-744-02927769"},"offer":{"cited_commentary_sources":19,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":28,"optional":true,"price_per_verified_person_usd":15,"price_usd":420,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"checkmate-744-nct02927769"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=checkmate-744-02927769","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/checkmate-744-nct02927769","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"standard","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-09T22:05:54.872739Z","notify_subscribers":false,"status":"corrected","summary":"Held-out review entries are rewritten as plain statements of what the edition does not yet include, and a transcription-garbled drug name in quotations carries its editorial correction in brackets."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":1},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":2,"title":"Primary endpoint: Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2"},{"claim_count":13,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":19,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":14,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":18,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":10,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":21,"coverage":"discussed","id":"A1","source_count":3,"title":"Risk selection, PET and investigational ctDNA"},{"claim_count":22,"coverage":"discussed","id":"A2","source_count":5,"title":"Selective transplant omission versus routine-care autograft"},{"claim_count":17,"coverage":"discussed","id":"A3","source_count":8,"title":"Modern ISRT contribution, planning and transplant-free endpoints"},{"claim_count":22,"coverage":"discussed","id":"A4","source_count":6,"title":"Alternative salvage strategies and the evidence threshold for omission"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":4,"title":"Pediatric-to-adult translation and evidence-generation models"},{"claim_count":21,"coverage":"discussed","id":"A6","source_count":4,"title":"UK access, prior exposure and relapse-dependent sequencing"},{"claim_count":18,"coverage":"discussed","id":"A7","source_count":3,"title":"Fertility, cardiovascular follow-up and lifelong survivorship"},{"claim_count":7,"coverage":"discussed","id":"A8","source_count":1,"title":"Family preferences, adolescent involvement and planning time"}],"counts":{"cited_sources":21,"claims_by_expression_type":{"comparison":21,"experience":14,"interpretation":36,"opinion":36,"primary_context":4,"question":14,"restatement":47,"uncertainty":18,"unspecified":7},"claims_by_kind":{"attributed_opinion":17,"counterview":1,"interpretation":21,"limitation":2,"objective_result":1,"protocol_statement":3,"source_observation":152},"evidence_units":120,"findings":7,"people_cited":21,"people_identity_verified":28,"people_total":30,"screened_sources":21,"verified_claims":197},"depth":"standard","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"Selective transplant avoidance is welcomed, but enthusiasm does not equal abandonment of autograft"},{"id":"F2","title":"Modern ISRT is being rehabilitated through a total-treatment toxicity argument"},{"id":"F3","title":"The evidence threshold is durable omission with a credible later-salvage strategy"},{"id":"F4","title":"PET-based selection is practical; ctDNA remains a proposed refinement rather than a validated omission rule"},{"id":"F5","title":"Access, prior exposure and relapse timing can override an otherwise attractive regimen"},{"id":"F6","title":"Reducing intensity does not remove the need for fertility, cardiology and lifelong survivorship support"},{"id":"F7","title":"Family fear of relapse can favor familiar intensive treatment despite the appeal of de-escalation"}],"medical_affairs_question":"How should scientific exchange distinguish a selected transplant-sparing option from an off-trial replacement for autograft?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Selective avoidance, not a transplant-free rule for every relapse"},{"id":"section-2","level":2,"title":"Modern ISRT and the complete toxicity burden"},{"id":"section-3","level":2,"title":"Durable omission, later salvage and the evidence needed for broader use"},{"id":"section-4","level":2,"title":"Response assessment: useful PET, conditional molecular refinement"},{"id":"section-5","level":2,"title":"Sequencing under access and prior-exposure constraints"},{"id":"section-6","level":2,"title":"Survivorship remains part of the treatment decision"},{"id":"section-7","level":2,"title":"Shared decisions may favor more treatment, and planning time is conditional"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2"},"identity":{"accepted_at":"2026-10-09T22:05:54.872739Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-09T22:22:13Z","record_hash":"089dd35e67e124c0a6e5e5b95559285b41b39451d83357d70afed1f70633349a","release_hash":"d8668b9245b2cc01a6e8a67fde3a2abf1444a1d51319e110374710fd7034c9a1","report_id":"erudio-nct02927769","run_id":"7d88290d-a242-4238-bcf7-24d0c90c6bba","schema_version":"5.0","slug":"checkmate-744-02927769","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"CheckMate 744 anchors clinicians’ discussion of which children, adolescents and young adults with relapsed or refractory classical Hodgkin lymphoma might be treated without an autologous stem-cell transplant. Topics include response-guided treatment selection, PET imaging and investigational ctDNA, radiotherapy’s place in salvage care, endpoints and evidence needed for transplant omission, and translation to adult practice. Clinicians also discuss prior treatment exposure, drug access, long-term toxicity, fertility, survivorship support and family involvement in treatment decisions. Coverage is limited to the supplied commentary sources.","meta_description":"21 HCP sources screened · 197 verified claims from 21 sources · 7 findings. Updated 2026-10-09.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-92b4de7ea8fdcbb9ecc9-46bbecfe"],"id":"F3","paraphrase":"In discussion of CheckMate 744 on X, a speaker asked whether transplant-free survival should be added as an endpoint.","publication_caveats":{"reason":"No source-specific publication caveats were supplied.","status":"not_set"},"source_channel":"x_thread","source_date":"2023-10-01","title":"The evidence threshold is durable omission with a credible later-salvage strategy"},{"cited_claim_ids":["claim-30c7cb19165e9c2f573f"],"id":"F4","paraphrase":"In a podcast discussion of CheckMate 744, the host asked how imaging, including PET, informs patient selection, treatment choice and duration.","publication_caveats":{"reason":"No source-specific publication caveats were supplied.","status":"not_set"},"source_channel":"podcast","source_date":"2025-04-17","title":"PET-based selection is practical; ctDNA remains a proposed refinement rather than a validated omission rule"}]},"publication":{"approved_at":"2026-10-09T22:22:13Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-09T23:06:00Z","summary":"An editorial bracket follows a transcription-garbled drug name in quotations: “epalumab [ipilimumab]”."},{"affected_ids":[],"date":"2026-10-09T23:06:00Z","summary":"Held-out review entries now state plainly what the edition does not yet include."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":6,"refresh_due_at":"2026-10-10T22:05:54.872739Z","retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:identity_queries:named_sources=22;queries=2","commentary:discovery_screen:discovery-screen-1;candidates=39;admitted=2","commentary:discovery_screened_out:youtube:video_id:ezMVti_1Sc4=Advanced-stage Hodgkin topic; no evidence of the relapsed pediatric trial.,youtube:video_id:shu4NNeAYM0=Frontline advanced-stage combination, not the target's relapsed population.,podcast:episode_id:99e4f0=General frontline ICI update; no sign of CheckMate 744.,youtube:video_id:2mxgmXK47-Q=R/R BV-nivolumab±ipilimumab outcomes describe a different study.,podcast:episode_id:74b2c5=BV-nivolumab-chemotherapy topic does not match the target regimen.,podcast:episode_id:28b43e=BV-dacarbazine or nivolumab discussion describes a different treatment compariso,x_thread:conversation_id:2006032707457785921=Early-stage nonbulky cHL study, unlike the target's R/R setting.,youtube:video_id:CXvMih_j17M=General advanced-stage treatment analysis; no target-trial signal.,youtube:video_id:VwaI42USNJY=S1826 follow-up concerns a different advanced-stage trial.,podcast:episode_id:232c00=Advanced-stage nivolumab-AVD findings do not match the target regimen.,youtube:video_id:1s17SpthApU=General targeted-therapy symposium; no target-trial signal.,youtube:video_id:kmikigLRAH0=Names the distinct ANIMATE trial in R/R cHL.,podcast:episode_id:7a55ec=General nivolumab-versus-brentuximab discussion, not the target combination stud,youtube:video_id:NIyeYiIvh5k=Pediatric R/R study adds ipilimumab; it is a different regimen.,x_thread:conversation_id:1701690951742238800=Broad R/R treatment-strategy discussion; no target-trial signal.,youtube:video_id:B84rforgXXw=Early-stage cHL study, not the target's relapsed/refractory population.,youtube:video_id:PyOvwlOTq1s=Names SWOG S1826, a different trial and treatment setting.,x_thread:conversation_id:1662957630459985927=General salvage-therapy review with no sign of this trial.,x_thread:conversation_id:1872717001120206879=General hematology year-in-review title does not identify this trial.,youtube:video_id:lCRKH-Yas50=General cHL/NLPHL update; no target-specific details.,x_thread:conversation_id:1934722697625206874=Names an elderly-patient S1826 analysis, a different trial.,youtube:video_id:WBpLURNGbxA=General pediatric Hodgkin management update; no target-specific details.,x_thread:conversation_id:1865510133708554370=General ASH cHL strategies post; no target-trial signal.,youtube:video_id:xoO1NSDzEzY=Discusses pembrolizumab after chemotherapy, not the target regimen.,youtube:video_id:FxBGBzN-Xq0=Nivolumab-AVD versus BV-AVD concerns a different treatment setting.,x_thread:conversation_id:1859411114938790194=Low-dose nivolumab discussion does not match the target regimen.,x_thread:conversation_id:1800616285291565290=Retrospective BV-chemotherapy analysis describes a different treatment approach.,youtube:video_id:IAYTFOTjhFo=Broad ASH meeting update; no indication it discusses this trial.,x_thread:conversation_id:1864559494644076546=Real-world low-dose nivolumab topic does not match this trial.,youtube:video_id:MC2q8E5zjx0=Childhood-cancer title gives no Hodgkin or target-trial indication.,x_thread:conversation_id:1729540056078078234=BV-nivolumab±ipilimumab RCT describes a different regimen and study.,youtube:video_id:DKkYaslSBpo=Names the distinct KEYNOTE-667 trial.,x_thread:conversation_id:1868771799481372778=Focuses on treatment failure after BV and checkpoint inhibitors.,x_thread:conversation_id:1868771310375252269=Broad R/R immunotherapy discussion; no target-trial signal.,x_thread:conversation_id:2049966447741243642=BV-nivolumab±ipilimumab phase 2 describes a different study.,youtube:video_id:CRVOsFoUi4I=General ASCO highlights; no Hodgkin or target-trial indication.,x_thread:conversation_id:1672690214194540545=Explicitly names SWOG S1826, not CheckMate 744.","commentary:indexed_source_unreadable:youtube:video_id:4abDCSOpY54:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","Held out after independent review: a passage of “Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse” at 14:47 (Cathy Burton). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Managing Hodgkin Lymphoma in 2026” (the speaker). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Managing Hodgkin Lymphoma in 2026” at 22:36 (Sairah Ahmed). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Managing Hodgkin Lymphoma in 2026” at 24:42 (Sairah Ahmed). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse” at 12:02 (Cathy Burton). What it says is not yet represented in this edition's verified claims.","Held out after independent review: passages of “Managing Hodgkin Lymphoma in 2026” at 26:40 (the speaker). What they say is not yet represented in this edition's verified claims."],"source_count":21,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","6 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","4 further source limits are recorded in the machine-readable scope of this record.","The reviewed material is not a census of HCP opinion. Some unnamed or differently transcribed trial discussions may be absent, and one potentially relevant video was inaccessible.","Several posts concern the same presentation, and audio/video versions contain overlapping remarks. Their number cannot establish independent clinical agreement or adoption.","Full text of the low-risk publication was unavailable; supplied abstract and registry context do not turn shared headlines or speaker summaries into independently established clinical conclusions.","Risk groups, endpoints, timepoints and subsequent therapies differ across the studies and summaries discussed. In particular, standard-risk R2 is transplant-based, and attributed low-risk outcome summaries should not be pooled or silently relabeled.","Long-term comparative toxicity and the consequences of checkpoint exposure in young patients remain uncertain in the commentary; favorable acute tolerability does not resolve them.","Professional context for Cathy Burton is incomplete in the supplied profile. Source naming supports attribution of the remarks, not additional claims about employment, credentials or current practice authority."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":3,"publication":1,"registry":1,"regulatory":0,"x_thread":14,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":19,"methods":1,"results":1},"count":21,"evidence_window":{"end":"2026-07-10","start":"2023-04-27"},"retrieval_snapshot":"2026-10-09T21:07:18.513276Z","timeline":[{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W21"},{"count":6,"week":"2023-W39"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2023-W52"},{"count":1,"week":"2024-W45"},{"count":2,"week":"2025-W01"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W49"},{"count":2,"week":"2026-W28"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT02927769:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02927769:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02927769:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02927769:sap:1","quote_policy":"short_quote_link_out"},{"id":"pubmed:36564047","quote_policy":"no_derivatives"},{"id":"pubmed:39745739","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"openfda:3904f8dd-1aef-3490-e48f-bd55f32ed67f:20251111","quote_policy":"short_quote_link_out"},{"id":"openfda:085dd54c-4212-d879-afef-ee52732a48c0:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:27d840","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8f5328","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a2902e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1651703533199138822:c9c03d35-3026-4d60-9d3b-b9955f07bbc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1662819110646865923:78f5f771-4fe7-4d2b-8f26-2c8a439d320d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665797464635371520:3e88834b-0a5f-4df5-afab-2081396a4a9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708518709990654442:26a60d9c-28da-4df7-be8e-90c9c8eab59f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708519513107706168:ea4b3775-6a21-4e74-bca9-a81a6e0e094b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708521428067455380:d16dbdb0-d88f-468f-bad5-fea6c4579550","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708521711862522031:c2dc583c-3380-4200-a023-8b8b14792da0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708522998842773905:5d24382f-d562-491b-af3d-5f999801081c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708523138387185968:95815524-88b7-4887-b68c-0a481ca96fb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708524352017506362:83c2d83e-dafc-4bc2-963e-d8cae0879b92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1722262657108242691:d1a13441-8012-49fa-b5ca-e5c81bb2863d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1739815415751082087:8ea78d12-b211-423c-91f4-f2127b26a3a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854923181800538171:74f63936-9155-4db7-92f4-8763436c8c13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1875631231834190083:3bf5b4b6-27b0-4e99-b68a-6c93efd8b7bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1875899709161877527:28c5d8ac-964c-46e3-8f77-bd8968ca2fe8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1878748968399650957:43b878ab-2518-4c66-84fd-5eb9ff1f37e1","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:MHcKZdzr2iU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Xmry4MAz3Q8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":21},"count":21,"evidence_window":{"end":"2026-07-10","start":"2023-04-27"},"retrieval_snapshot":"2026-10-09T21:07:18.513276Z","timeline":[{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W21"},{"count":1,"week":"2023-W23"},{"count":7,"week":"2023-W39"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2023-W52"},{"count":1,"week":"2024-W45"},{"count":2,"week":"2025-W01"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W49"},{"count":2,"week":"2026-W28"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":["Adcetris"],"label":"brentuximab vedotin","slug":"brentuximab-vedotin"},{"brand_names":["Treanda","Bendeka"],"label":"bendamustine","slug":"bendamustine"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Hodgkin lymphoma","slug":"hodgkin-lymphoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"CheckMate 744","aliases":["CheckMate 744","A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)"],"brief_title":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","collaborators":["Seagen Inc."],"conditions":["Hodgkin Disease"],"enrollment":{"count":72,"type":"ACTUAL"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"Nivolumab","synonyms":["BMS-936558","Opdivo"],"type":"BIOLOGICAL"},{"name":"brentuximab vedotin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"bendamustine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"}],"nct_id":"NCT02927769","official_title":"Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2024-05-28","type":"ACTUAL"},"primary_endpoints":[{"description":"The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who stopped study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method","measure":"Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1","timeFrame":"From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)."},{"description":"Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \\>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an \"event\" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior \"event\" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.","measure":"Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1","timeFrame":"At 3 years post first dose of study therapy"},{"description":"The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method","measure":"Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2","timeFrame":"From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)"}],"registry_last_updated":"2025-02-10","registry_url":"https://clinicaltrials.gov/study/NCT02927769","short_name":"CheckMate 744","short_name_basis":"registry_acronym","sponsor":"Bristol-Myers Squibb","start_date":{"date":"2017-03-28","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"CA209-744","type":"sponsor_study_id"},{"id":"2016-002347-41","type":"eudract_number"},{"id":"2016","type":"nih"}],"study_type":"INTERVENTIONAL"}}}